BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

NVO upcoming catalysts

Novo Nordisk A/S: 4 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (2 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 14 readout(s) and 8 FDA event(s). Subscribe to NVO (.ics).

Drugs: Semaglutide, Ziltivekimab, Tirzepatide, NNC0662-0419, UBT251, Insulin icodec, Insulin glargine, Insulin aspart

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-14 est.P2Novo Nordisk A/S NVONCT07184632 A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityOverweight; Obesityactive not recruiting224
2027-01-14 est.P2Novo Nordisk A/S NVONCT07395687 A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or ObesityOverweight; Obesityrecruiting333
2027-01-25 est.P3Novo Nordisk A/S NVONCT07076199 A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With InsDiabetes Mellitus, Type 1active not recruiting877
2027-01-29 est.P3Novo Nordisk A/S NVONCT06118281 ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackCardiovascular Risk; Acute Myocardial Infarction (AMI)active not recruiting10000

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-10-23FDA approvalapprovedNOVO NORDISK INC NVOAWIQLI FLEXTOUCHApproved 2026-10-23: AWIQLI FLEXTOUCH (BLA761326 SUPPL1)
2026-03-26FDA approvalapprovedNOVO NORDISK INC NVOAWIQLI FLEXTOUCHApproved 2026-03-26: AWIQLI FLEXTOUCH (BLA761326 ORIG2)
2026-03-19FDA approvalapprovedNOVO NVOWEGOVY WEGOVY FLEXTOUCH WEGOVY HDApproved 2026-03-19: WEGOVY; WEGOVY FLEXTOUCH; WEGOVY HD (NDA215256 SUPPL29)
2026-02-27FDA approvalapprovedNOVO NORDISK INC NVOSOGROYAApproved 2026-02-27: SOGROYA (BLA761156 SUPPL15)
2026-02-27FDA approvalapprovedNOVO NORDISK INC NVOSOGROYAApproved 2026-02-27: SOGROYA (BLA761156 SUPPL14)
2026-02-27FDA approvalapprovedNOVO NORDISK INC NVOSOGROYAApproved 2026-02-27: SOGROYA (BLA761156 SUPPL12)
2025-12-22FDA approvalapprovedNOVO NVOWEGOVYApproved 2025-12-22: WEGOVY (NDA218316 ORIG1)
2025-11-21FDA approvalapprovedNOVO NVOWEGOVY WEGOVY FLEXTOUCH WEGOVY HDApproved 2025-11-21: WEGOVY; WEGOVY FLEXTOUCH; WEGOVY HD (NDA215256 SUPPL23)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-01 est.P3Novo Nordisk A/S NVONCT06200207 A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationHeart Failure; Systemic Inflammationactive not recruiting673
2026-09-03P3Novo Nordisk A/S NVONCT05636176 A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationHeart Failureterminated4874
2026-09-01 est.P2Novo Nordisk A/S NVONCT06717698 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseChronic Kidney Diseaserecruiting465
2026-06-29P3Novo Nordisk A/S NVONCT07271251 A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People WiType 2 Diabetescompleted267
2026-06-26P2Novo Nordisk A/S NVONCT06797869 A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyDiabetes Mellitus, Type 2; Diabetic Peripheral Neuropathycompleted142
2026-06-09P3Novo Nordisk A/S NVONCT05021835 ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationCardiovascular Risk; Chronic Kidney Disease; Inflammationcompleted6385
2026-06-02P3Novo Nordisk A/S NVONCT06534411 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLDiabetes Mellitus, Type 2completed1023
2026-04-22P3Novo Nordisk A/S NVONCT06388187 A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightObesitycompleted300
2026-04-21P3Novo Nordisk A/S NVONCT05135559 A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without InhibitorsHaemophilia A and B With and Without Inhibitorsactive not recruiting153
2026-03-09P2Novo Nordisk A/S NVONCT05725902 Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell DiseaseSickle Cell Diseasecompleted12
2026-03-04P3Novo Nordisk A/S NVONCT06221969 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin WithType 2 Diabetescompleted1024
2025-12-08P3Novo Nordisk A/S NVONCT06131437 A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightObesitycompleted809
2025-11-21P2Novo Nordisk A/S NVONCT06409130 Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseAlcohol-related Liver Diseasecompleted270
2025-11-19P3Novo Nordisk A/S NVONCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes TType 2 Diabetes Mellituscompleted2734

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.